This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. The new and innovative needle measures at just 34G x 3.5mm.
The FDA is planning two listening sessions to allow manufacturers, developers, health care providers, researchers, and other interested parties to learn more about the purpose and function of the DHCoE. Approval of the Month: FDA Approves First Closed-Loop Monitoring and DrugDelivery Device.
There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drugdelivery and prefilled syringe market in the coming years.
The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.
LillyDirect Pharmacy Solutions, Eli Lilly’s direct-to-consumer (DTC) drugs website, is teaming up with Amazon Pharmacy to deliver select medications to people’s homes. The drugs include Lilly’s newly approved GLP-1 obesity drug Zepbound (tirzepatide), around a dozen of the company’s insulins and migraine drug Emgality (galcanezumab).
However, several drugdelivery devices that enable patients to self-administer their respective medications are now available. Subcutaneous drugdelivery systems – the helping hand for patients. The emergence of safer and patient-friendly devices is acting as a strong enabler for subcutaneous delivery of therapeutics.
Autoinjector As Emerging DrugDelivery Device. The field is presently witnessing several innovations, such as LED / LCD-based visualization, Bluetooth connectivity, dosage recording, safety lock, visual / audible drugdelivery confirmation notifications, and automatic drug reconstitution.
These innovative instruments combine precision, convenience, and patient-centered design to revolutionize drugdelivery. These devices are equipped with advanced features like programmable dosing, connectivity to mobile apps, and safety mechanisms to ensure accurate and controlled drugdelivery.
It is another effort from CDRH’s Digital Health Center of Excellence to provide structure and guidance to participants across the connected device playing field, including both delivery organizations as well as manufacturers.
The need for firms to make a reasonable profit is paramount in today’s world; healthy pharmaceutical research and manufacturing are the keys to ending disease, curing chronic conditions, and discovering new therapies and vaccines that address the latest medical challenges.
PBMs serve as intermediaries between insurers, pharmacies and drugmanufacturers, negotiating discounts and managing drug formularies. While PBMs were originally intended to lower costs and streamline drugdelivery, critics argue that their practices often lead to inflated prices and restricted access for consumers.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content